$1.79
-0.14 (-7.25%)
Open$1.87
Previous Close$1.93
Day High$2.04
Day Low$1.73
52W High$46.00
52W Low$1.74
Volume—
Avg Volume11.1K
Market Cap2.99M
P/E Ratio—
EPS$-25.77
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,619.0% upside
Current
$1.79
$1.79
Target
$30.77
$30.77
$21.48
$30.77 avg
$35.71
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 18.39M | 59.60M | 759.7K |
| Net Income | -1,407,587,770 | -4,105,084,228 | -24,634 |
| Profit Margin | -7,652.8% | -7,270.1% | -3.2% |
| EBITDA | -1,182,760,510 | -3,641,032,030 | -38,889 |
| Free Cash Flow | — | — | -29,815 |
| Rev Growth | -69.1% | -69.1% | +6.1% |
| Debt/Equity | — | — | 0.67 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |